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Assessing the degree to which chronic GVHD (cGVHD) may
limit range of joint motion (ROM) needs to be accomplished re-
liably, simply, and in a clinically meaningful way. We evaluated
NIH recommended scales and a photographic ROM (P-ROM)
scale [Carpenter PA, Blood 2011] for their correlation with pro-
vider (MD) and patient (PT) perceptions of joint change.
Patients andMethods:As part of a multicenter, prospective, lon-
gitudinal observational cohort, 458 patients receiving systemic
cGVHD therapy were studied; 177/327 (54%) with baseline
P-ROM had limited ROM defined by any 1-6 P-ROM score
(7 5 full ROM) at the wrists, elbows, shoulders or, 1-3 score
(4 5 full) at the ankles. NIH cGVHD joint scoring was categor-
ical: 0 5 full ROM (or not limited by cGVHD) and scores 1 to
3 were based upon MD opinion of PT extremity tightness, de-
gree of reduction in both ROM and activities of daily living.
At follow-up visits, as anchors, PT and MD rated separately their
perception of change in joint cGVHD. Multivariable models
were used to measure associations between MD/PT perceived
changes (improved, stable, worse) and changes in P-ROM mea-
sures, NIH joint scores, and other items in the 2005 NIH con-
sensus recommendations.
Results:ROM limitation was common (see Table). It was seen in
patients with a longer duration of cGVHD, and was associated
(p\0.01) with NIH skin response measures, the NIH 0-3 joint
score, Lee energy subscale but not the Human Activity Profile,
2-minute walk test or grip strength. Compared to previous visits
with ROM limitation (N 5 369 visits), both MDs (60%) and
PTs (47%) were more likely to report perceived improvement
than worsening (4% MD, 9% PT). In multivariable analyses,
MD perceptions of change in joint cGVHD were best predicted
by P-ROM wrist score (p 5 0.003), NIH 0-3 joint score
(p\0.001) and SF36 bodily pain subscale (p 5 0.01). PT per-
ceptions of changes in joint cGVHD were predicted by SF36
bodily pain score (p 5 0.01). Changes in the extrapolated
Rodnan skin score and the NIH 0-3 skin score were not asso-
ciated with perceived changes in joint cGVHD by MD and PT.
Conclusions: Joint involvement is common and should be assessed
in all patients with cGVHD. The NIH joint score (1 item), P-ROM
scale (4 items) and the SF36 bodily pain subscale (2 items) appeared
to have the most clinical utility for measuring symptom change.
Finer gradations within the P-ROM’s clinically relevant range
(scores 4-7) may improve its sensitivity to change.Table. Analysis of Categorical and Continuous Variables as-
sociated with ROM
ROM notMeasuresROM involved
(N 5 177)involved
(N 5 150) P valueWrist P-ROM Score (‘‘Prayer position’’)(%)7 (full) 40 1006 40 05 11 04 3 03 1 02 3 01 2 0Total involved 60 0 NA*(Continued )Table. (Continued)MeasuresROM involved
(N 5 177)ROM not
involved
(N 5 150) P valueShoulder Abduction P-ROM Score (%)7 (full) 57 1006 27 05 12 04 2 03 1 02 0 01 1 0Total involved 43 0 NA*Elbow Extension P-ROM Score (%)7 (full) 69 1006 20 05 8 04 2 03 0 02 1 01 0 0Total involved 31 0 NA*Ankle Dorsiflexion P-ROM Score4 (full) 39 1003 54 02 7 01 0 0Total involved 61 0 NA*NIH Skin Response Measures (%BSA),
Mean (SD)Erythema 5.0 (15.6) 9.7 (20.1) .009Moveable sclerosis 4.6 (10.3) 0.8 (4.2) <.0001Non-moveable sclerosis 3.1 (8.8) 0.0 (0.0) <.0001Lee Energy Score, Median (range) 35.7 (0.0-100) 25.0 (0.0-75.0) .002*Comparisons for these measures are not meaningful because they are
used to define joint involvement. Abbreviations: ROM, range of motion;
BSA, body surface area415
INTERRUPTION OF THE IFNgR/CXCR3 AXIS RESULTS IN ALTERED T CELL
TRAFFICKING IN VIVO AND ABROGATION OF GVHD WHILE MAINTAIN-
ING A ROBUST GVL RESPONSE
Choi, J., Ziga, E.D., Ritchey, J., Collins, L., Prior, J., Piwnica-
Worms, D., DiPersio, J.F. Washington University School of Medicine
The goal of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is to minimize graft-versus-host disease (GvHD) while
maintaining a beneficial graft-versus-leukemia (GvL) effect. This
can be achieved by infusing regulatory T cells (Tregs) which sup-
press GvHD but have only limited effects on GvL. Unfortunately,
Tregs exist in low frequency in the peripheral blood, are costly to pu-
rify and expand, and after expansion are difficult to isolate due to the
lack of cell surfacemarkers. Thus, alternative therapeutic approaches
are needed.
Using an MHC-mismatched GvHDmodel, B6 (H-2b)/ Balb/c
(H-2d), we demonstrated that infusion of IFNgR deficient
(IFNgR-/-) allogeneic donor T cells induced significantly less
GvHD, compared to WT T cells, as determined by survival (74%
vs. 0%; p 5 0.0004), weight loss and percentages of B220+ B cells
(12.4% vs. 3.8%; p 5 0.0205), CD3+ T cells (14.3% vs. 4.3%; p 5
0.0025) in blood. Of note was that the IFNgR-/- donor T cells in-
duced a robust GvL effect in both systemic leukemia and solid tumor
models using luciferase-expressing A20 cells derived from Balb/c.
We found that IFNgR-/- T cells responded normally to allogeneic
antigens in vitro, based on mixed lymphocyte reactions, and ex-
pressed similar levels of granzyme B, compared to WT T cells. Us-
ing bioluminescence imaging (BLI) and luciferase-transduced WT
and IFNgR-/- T cells, we observed that IFNgR-/- T cells trafficked
primarily to the spleen while WT T cells trafficked to gastrointesti-
nal tract and lymph nodes, which are major GvHD target organs.S357
